Kura Oncology's Darlifarnib Shows Strong Early Data in KRAS-Mutant Cancers, Expands Platform Strategy
Event summary
- Preliminary Phase 1a data show darlifarnib + adagrasib achieved 67% ORR in pancreatic cancer, 50% in NSCLC, and 29% in KRAS inhibitor-naïve colorectal cancer.
- Clinical activity observed in both KRAS inhibitor-naïve and pretreated patients.
- Kura plans a platform study to evaluate darlifarnib across multiple targeted therapy combinations, starting with darlifarnib + daraxonrasib in KRAS-mutant pancreatic cancer in early 2027.
- Data presented at the 2026 ASCO Annual Meeting support darlifarnib's potential as a foundational combination platform for KRAS-mutant cancers.
The big picture
Kura Oncology's data reinforces the growing trend of combination therapies in precision oncology, particularly for KRAS-mutant cancers. The company's platform study approach aims to accelerate development and potentially establish darlifarnib as a backbone therapy in this rapidly evolving treatment landscape. The strategic move comes as the KRAS inhibitor market expands with multiple next-generation approaches advancing through clinical development.
What we're watching
- Combination Strategy
- Whether darlifarnib can sustain its efficacy across multiple targeted therapy settings and disease indications.
- Regulatory Pathway
- The pace at which Kura can advance successful combinations into dedicated registrational studies.
- Competitive Landscape
- How Kura's platform strategy positions it against evolving RAS inhibitor approaches in the KRAS treatment landscape.
Related topics